As part of its revised strategic plan, Crossject has expanded its partnership with CENEXI to fill and finish all of Crossject’s products in all regions for a period of five years, with a potential extension up to 10 years. Also, the timelines for its expected regulatory submissions have shifted across the board; most notably, the EU filing for ZENEO Methotrexate has been pushed back from H216 to H218 due to its non-emergency nature and higher requirement for manufacturing resources than
09 Dec 2016
Timeline adjustments
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Timeline adjustments
Crossject SA (ALCJ:PAR) | 0 0 (-3.4%) | Mkt Cap: 38.7m
- Published:
09 Dec 2016 -
Author:
Maxim Jacobs -
Pages:
6
As part of its revised strategic plan, Crossject has expanded its partnership with CENEXI to fill and finish all of Crossject’s products in all regions for a period of five years, with a potential extension up to 10 years. Also, the timelines for its expected regulatory submissions have shifted across the board; most notably, the EU filing for ZENEO Methotrexate has been pushed back from H216 to H218 due to its non-emergency nature and higher requirement for manufacturing resources than